1. Transcriptome profiling of tolerogenic dendritic cells conditioned with dual mTOR kinase inhibitor, AZD8055
   Su Shao et al, 2020, International Immunopharmacology CrossRef
2. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
   Raghvendra M. Srivastava et al, 2017, Clinical Cancer Research CrossRef
3. 4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression
   Hampartsoum B. Barsoumian et al, 2016, PLOS ONE CrossRef
4. 4-1BB agonism: adding the accelerator to cancer immunotherapy
   Cariad Chester et al, 2016, Cancer Immunology, Immunotherapy CrossRef
5. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
   Sevda Jafari et al, 2020, Cellular and Molecular Life Sciences CrossRef
6. Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A’s: Abundance, Activation and Antigen-Delivery
   Aleksandar Murgaski et al, 2019, Cancers CrossRef
7. Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9
   Neil S. Lagali et al, 2018, Scientific Reports CrossRef
8. PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
   Quentin Wright et al, 2021, Cancers CrossRef
9. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
   Todd Bartkowiak et al, 2015, Frontiers in Oncology CrossRef
10. Rationale for anti-CD137 cancer immunotherapy
    Amani Makkouk et al, 2016, European Journal of Cancer CrossRef
11. The Roles of CD137 Signaling in Atherosclerosis
    In-Hyuk Jung et al, 2016, Korean Circulation Journal CrossRef